Fidelis Capital Partners LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

Fidelis Capital Partners LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 5.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 24,518 shares of the biopharmaceutical company’s stock after selling 1,317 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Pfizer were worth $642,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the fourth quarter worth approximately $28,000. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares in the last quarter. Noble Wealth Management PBC purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $31,000. Finally, Sierra Ocean LLC bought a new position in Pfizer in the fourth quarter worth approximately $34,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on PFE shares. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 0.8 %

Pfizer stock opened at $26.21 on Tuesday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The business has a fifty day moving average price of $26.34 and a 200-day moving average price of $27.30. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $148.53 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.56%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.